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The problem 
Helicobacter pylori infects the gastric mucosa of half the human population, leading to chronic 
gastric inflammation in all and clinically important adverse outcomes in a sizable minority. While 
most infections with this gram-negative bacterium are not associated with symptoms, gastric or 
duodenal ulcers ultimately develop in approximately 10% of colonized individuals, with gastric 
adenocarcinoma or mucosal-associated lymphoid tissue lymphoma occurring in about 1%, 
decades after the initial infection. H. pylori infection is unevenly distributed, being most prevalent 
in resource-poor countries (in the range of 70-90%) and in as few as 10% or less of some 
Western populations [1]. Excitement about developing a vaccine based on the genome of H. 
pylori abated soon after the sequence was published, when effective antibiotic therapy was 
discovered. Unfortunately, the multidrug regimens that are required to eradicate infection 
currently remain out of reach for most of the affected patients, they do not prevent re-infection, 
and antibiotic-resistant strains are increasingly common [2].  
 
The recent emergence of resistance to antimicrobial therapy has stirred new interest in the 
development of an anti-H. pylori vaccine [3], but the complex immunopathogenesis of H. pylori 
has frustrated successful vaccine development. H. pylori elicits an intense inflammatory 
response to infection, involving the recruitment of multiple innate and adaptive immune cell 
populations to the stomach. However, persistent infection for the lifetime of the host usually 
follows, demonstrating that this bacterium successfully evades natural host defenses.  Most 
evidence points to an initial pro-inflammatory response mounted by type 1 T helper CD4+ cells 
(Th1) producing interferon-γ that is eventually dampened by CD4+CD25high regulatory T cells 
(Treg) expressing FoxP3 [4]. As a result, the pathogen is not eradicated, and persistent infection 
develops, contributing to the development of chronic gastritis. A successful vaccine, be it 
prophylactic or therapeutic, must be able to tip the immune system balance in favor of an 
immune Th1 response that will overcome the immunosuppressive properties of Tregs naturally 
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induced by H. pylori. Neither whole inactivated H. pylori, bacterial vectored vaccines expressing 
H. pylori proteins, nor recombinant subunit vaccines have demonstrated protective immunity in 
clinical trials despite their recognition by humoral and cell-mediated arms of the immune system. 
The time is ripe for a novel approach to vaccine design that overcomes the limitations of these 
conventional approaches. 
 
A promising solution 
Advances in the fields of genomics and computation have led to the emergence of a new 
approach to vaccine development, better known as reverse vaccinology or genome-to-vaccine 
design. The field is only about 10 years old, yet the first reverse vaccinology product, Novartis’ 
Bexsero, a vaccine against meningococcus B, is about to be licensed in Europe. One of the 
major hurdles facing reverse vaccinologists is choosing the best candidate immunogens from 
the wealth of targets provided by whole-genome sequencing. The number of antigens 
comprised by bacterial pathogens can be quite large. The genetic diversity of hypermutating 
viruses with much smaller genomes can also pose a significant problem. Moreover, the genomic 
landscape is amplified by diversity within a single species [5].  
 
Bioinformatics tools developed to harness the emerging genomic sequence “haystack” can be 
used to identify potentially immunogenic proteins by their predicted subcellular localization (e.g. 
membrane proteins or secreted proteins) or homology to virulence factors of related pathogens. 
Together with proteomics data describing antigen expression abundance and kinetics, these 
tools narrow down ‘antigen-space’ considerably but they themselves do not provide 
immunological direction to vaccine antigen selection. Perhaps the most utilitarian tool, in this 
regard, is the T-cell epitope predictor. A T-cell epitope peptide derived from an invading 
pathogen interfaces with a major histocompatibility complex (MHC) molecule at an antigen 
presentation cell surface and a T cell receptor at the T cell surface. This interaction is essential 
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for activation of protective adaptive immune responses. CD8+ and CD4+ T cells play important 
roles in containing infections and protection after re-exposure. CD4+ T cell responses are critical 
for robust CD8+ T cell proliferation and function and for their differentiation into memory cells 
[6,7]. Moreover, CD4+ T cell responses help B cells to produce antibodies that are the mediators 
of protection in all currently approved human vaccines [8]. Thus, a T-cell epitope predictor may 
identify pathogen-derived sequences that are good vaccine antigens and/or identify key T cell 
epitopes that are important adjuncts for effective humoral immune response. Furthermore, as 
cognate T cell help improves the quality and kinetics of antibody responses, T-cell epitope 
predictors, when used to identify proteins that have the greatest number of T cell epitopes, may 
be particularly useful for fishing out good candidates for whole antigen vaccines.  
 
We have developed a genome-to-vaccine strategy, with a central role for T-cell epitope 
predictors, that identifies immunogenic and protective T-cell epitopes. While it can be 
specifically tailored to a microbe’s particular immunopathogenic profile, this approach can be 
generally applied to any pathogen, according to the following steps: 1) Genomes are 
computationally mined to identify genes that encode proteins with promising antigenic properties 
such as secretion, up-regulated expression, reported immunogenicity and virulence [9,10]. 
Alternatively, with no experimental bias introduced, complete open reading frame datasets can 
be analyzed. 2) Immunoinformatics tools are then used to discover sequences likely to bind to 
MHC proteins for presentation to T cells. To cover a large swath of MHC polymorphisms, 
‘supertype’ alleles are screened. For personalized vaccine design, the particular MHC type of an 
individual would be considered. Depending on the correlate of protective immunity that is 
desired, proteins can be triaged by epitope content (those with more T cell epitopes may be 
better immunogens), or epitopes can be selected and used as the vaccine “payload.”  3) Where 
epitopes are being used to vaccinate, the next step is to synthesize selected sequences as 
peptides and evaluate for MHC binding and antigenicity in infection survivors or vaccinees. 4) 
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Finally, prototype vaccines are designed, constructed and evaluated for immunogenicity and 
efficacy in humanized mice [11]. If epitope-driven vaccines are the objective, the resulting 
epitopes may be formulated as multiple peptides, as concatamers in the form of DNA or 
delivered as multi-epitope protein vaccines. Clearly, this strategy strips a pathogen down to the 
minimal essential sequence information needed to generate immunity, thereby removing the 
pathogen’s inherent adjuvant and delivery properties that make it naturally immunogenic. 
Building these features back into the final product is necessary, of course, but a key advantage 
of epitope-based vaccine design is that it allows for the subsequent selection of best-in-class 
adjuvant and delivery technologies.  
 
We have applied this genomes-to-vaccine approach to develop an H. pylori therapeutic vaccine 
that was evaluated in the p27 knockout mouse model of gastric cancer induced by chronic H. 
pylori infection [12,13]. The H. pylori J99 and 26695 genomes were screened for CD4+ T-cell 
epitopes that bind both human and mouse MHC, using the predictor algorithm EpiMatrix. To 
identify epitopes with potential to recognize multiple MHC types for broad coverage of the MHC-
diverse human population, we used the ClustiMer algorithm, which finds regions of a protein 
with high epitope density. Epitope cluster predictions were experimentally validated for MHC 
binding and T cell reactivity in p27 knockout mice infected with the mouse-adapted H. pylori 
strain SS1. Immunoreactive epitopes that bound MHC and that were also present in strain SS1 
were assembled into a multi-epitope vaccine in DNA and peptide formats using a heterologous 
prime-boost immunization strategy. The multi-epitope vaccine administered intranasally to SS1-
infected mice induced a broad immune response as determined by interferon-γ production in 
ELISpot assays; much broader, in fact (when examining immune responses to the epitopes), 
than the response elicited by a whole bacterial lysate which would have included the proteins 
from which the epitopes were derived. This result was paralleled in H. pylori burden in mice 
immunized intranasally, which exhibited a significant reduction compared with mice vaccinated 
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with whole bacterial lysate. Histopathological indices of inflammation and gastric cellular 
damage were low at the distal timepoint that was evaluated, and not significantly different 
among the experimental groups.  
 
Emerging issues in epitope selection  
We have long considered T-cell epitopes that are conserved between self and infectious 
pathogens to potentially drive cross-reactive T cells toward immune disequilibrium under the 
inflammatory conditions of vaccination. These sequences have therefore been excluded from 
our vaccines. Our current thinking about T-cell epitope selection is evolving as new data 
demonstrate that the human microbiome actively shapes immune responses. Post-thymic 
educated regulatory T cells play a critical role in orchestrating this interaction via antigen 
presentation [14], and thus we believe careful consideration must be given to T-cell epitope 
sequences conserved between commensals and infectious pathogens, much in the same way 
that we do for self. As the gut microbiome is estimated to contain approximately 33 million 
genes, the amount of sequence data to sort through to identify the molecular specificities of 
these T cells is staggering. We are now beginning to design a new class of computational tools 
and data analysis methods to handle this enormous task. 
 
Conclusion 
The utility of the genome-to-vaccine approach for developing vaccines for pathogens has been 
emerging from our work and others [15,16,17,18]. The convergence of genomics, bioinformatics 
and immunology has expanded our vaccine design toolkit and the results generated thus far 
suggest that there is new hope for tackling the many pathogens against which we currently lack 
effective vaccines. Proof-of-concept studies for a T-cell epitope-driven H. pylori vaccine 
demonstrate this potential, and we expect that fine-tuning the epitope selection criteria will help 
epitope-based vaccines take their place amongst conventional vaccines that have already had 
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so great an impact on human health. 
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